Workflow
Earnings Estimate
icon
Search documents
Shell to Report Q1 Earnings: What's in Store for the Stock?
ZACKS· 2025-05-01 12:30
Shell plc (SHEL) is set to release first-quarter results on May 2. The current Zacks Consensus Estimate for the to-be-reported quarter is earnings of $1.59 per share on revenues of $79.9 billion.Let’s delve into the factors that might have influenced the integrated energy behemoth’s results in the March quarter. But it’s worth taking a look at SHEL’s previous-quarter performance first.Highlights of Q4 Earnings & Surprise HistoryIn the last reported quarter, Europe’s largest oil company missed the consensus ...
Compared to Estimates, MGIC (MTG) Q1 Earnings: A Look at Key Metrics
ZACKS· 2025-04-30 23:35
Core Viewpoint - MGIC Investment (MTG) reported a slight increase in revenue and a notable rise in EPS for the quarter ended March 2025, although revenue fell short of analyst expectations [1]. Financial Performance - Revenue for the quarter was $305.49 million, reflecting a year-over-year increase of 0.9% [1]. - EPS was reported at $0.75, an increase from $0.65 in the same quarter last year, resulting in a surprise of +13.64% over the consensus estimate of $0.66 [1]. - The revenue reported was -1.46% below the Zacks Consensus Estimate of $310.03 million [1]. Key Metrics - GAAP underwriting expense ratio was 22.5%, lower than the average estimate of 24.4% based on two analysts [4]. - GAAP loss ratio stood at 3.9%, significantly below the average estimate of 16.2% [4]. - Net premiums earned were $243.72 million, slightly below the average estimate of $245.41 million, with a year-over-year change of +0.4% [4]. - Other revenue was reported at $0.33 million, which is -31.3% lower than the average estimate of $0.50 million [4]. - Net investment income was $61.44 million, compared to the average estimate of $64.12 million, marking a year-over-year increase of +2.8% [4]. Stock Performance - Shares of MGIC have returned -2% over the past month, while the Zacks S&P 500 composite experienced a -0.2% change [3]. - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3].
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
ZACKS· 2025-04-30 15:20
Core Viewpoint - The Cigna Group is expected to report first-quarter 2025 results on May 2, 2025, with earnings estimated at $6.39 per share and revenues of $60.8 billion, indicating a year-over-year revenue growth of 6.2% despite a slight decline in earnings [1][2]. Financial Performance - The first-quarter earnings estimate has decreased by 2 cents over the past 60 days, reflecting a year-over-year decline of 1.2% [1]. - For the full year 2025, the revenue estimate is $252.36 billion, representing a 2.1% increase year over year, while the EPS estimate is $29.61, indicating an 8.3% growth [2]. Earnings Prediction - The current model does not predict a definitive earnings beat for Cigna, with an Earnings ESP of -0.34% and a Zacks Rank of 3 (Hold) [3]. Revenue Drivers - Cigna's revenues are anticipated to benefit from strong pharmacy revenues, particularly from the specialty pharmacy business within the Evernorth segment, with an expected 8.4% improvement in pharmacy revenues year over year [5]. - The Evernorth Health Services segment is projected to generate revenues of $50.5 billion, indicating a 9.3% growth from the prior year [6]. Challenges - The consensus estimate for premiums indicates an 8.6% decrease year over year, and Cigna Healthcare revenues are expected to decline by 8.5% [7]. - The total medical customers are projected to decrease to 18.3 million from 19.2 million a year ago [7]. - A decline in net investment income is expected, with an 11.9% year-over-year decrease anticipated [7]. - Elevated medical costs due to higher utilization trends and unit cost inflation are likely to impact margins, with the medical care ratio (MCR) expected to rise to 82.39% from 79.9% a year ago [8].
Earnings Preview: Walt Disney (DIS) Q2 Earnings Expected to Decline
ZACKS· 2025-04-30 15:07
Wall Street expects a year-over-year decline in earnings on higher revenues when Walt Disney (DIS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 7, 2025, might help the stock move higher if these key numbers are better than expectatio ...
Analysts Estimate Greystone Housing Impact Investors (GHI) to Report a Decline in Earnings: What to Look Out for
ZACKS· 2025-04-30 15:07
Core Viewpoint - Greystone Housing Impact Investors (GHI) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended March 2025, with the actual results being crucial for its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on May 7, with a consensus EPS estimate of $0.21 per share, reflecting a 50% decrease year-over-year. Revenues are projected to be $24.68 million, representing a 10.3% increase from the previous year [3][4]. Estimate Revisions - The consensus EPS estimate has been revised down by 44.12% over the last 30 days, indicating a significant reassessment by analysts [4][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%. The stock currently holds a Zacks Rank of 5, complicating predictions of an earnings beat [11][12]. Historical Performance - In the last reported quarter, GHI exceeded the expected earnings of $0.12 per share by delivering $0.34, resulting in a surprise of +183.33%. Over the last four quarters, the company has beaten consensus EPS estimates twice [12][13]. Conclusion - GHI does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, suggesting that investors should consider additional factors before making investment decisions [16].
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics
ZACKS· 2025-04-30 14:21
Core Viewpoint - Analysts forecast a decline in Biogen Inc.'s quarterly earnings and revenues, indicating potential challenges for the company in the upcoming earnings report [1]. Earnings and Revenue Estimates - Biogen is expected to report earnings of $3.32 per share, reflecting a year-over-year decline of 9.5% [1]. - Revenue is anticipated to be $2.23 billion, showing a decrease of 2.6% compared to the same quarter last year [1]. - Over the past 30 days, the consensus EPS estimate has been adjusted upward by 0.1%, indicating a slight positive reassessment by analysts [2]. Product-Specific Revenue Estimates - Revenue from Multiple Sclerosis (MS) product TYSABRI is estimated at $364.47 million, down 15.5% year-over-year [5]. - Revenue from Rare Disease product SPINRAZA is projected at $365.01 million, up 7% year-over-year [5]. - Total net revenue from products is expected to reach $1.66 billion, reflecting a decline of 3% from the previous year [6]. - Revenue from Anti-CD20 therapeutic programs is estimated at $411.57 million, indicating a growth of 4.5% year-over-year [6]. Regional Revenue Estimates - Revenue from MS product TYSABRI in the United States is forecasted at $191.97 million, down 10.2% year-over-year [9]. - Revenue from MS product Fumarate (TECFIDERA) in the United States is expected to be $31.40 million, reflecting a significant decline of 28.1% [9]. - Revenue from SPINRAZA in the United States is projected at $160.72 million, up 8.2% year-over-year [7]. - Revenue from MS product Interferon in the United States is expected to be $119.70 million, down 14.4% year-over-year [10]. Market Performance - Over the past month, Biogen shares have decreased by 9%, contrasting with the Zacks S&P 500 composite's slight decline of 0.2% [10]. - Biogen holds a Zacks Rank of 3 (Hold), suggesting that its performance may align with the overall market in the near term [10].
Wall Street's Insights Into Key Metrics Ahead of ON Semiconductor Corp. (ON) Q1 Earnings
ZACKS· 2025-04-30 14:20
Analysts on Wall Street project that ON Semiconductor Corp. (ON) will announce quarterly earnings of $0.51 per share in its forthcoming report, representing a decline of 52.8% year over year. Revenues are projected to reach $1.41 billion, declining 24.6% from the same quarter last year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Be ...
Wall Street's Insights Into Key Metrics Ahead of Exxon (XOM) Q1 Earnings
ZACKS· 2025-04-30 14:20
Core Viewpoint - Analysts forecast Exxon Mobil (XOM) will report quarterly earnings of $1.72 per share, reflecting a year-over-year decline of 16.5%, with anticipated revenues of $84.49 billion, an increase of 1.7% compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 8.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Sales and other operating revenue' will reach $84.12 billion, indicating a year-over-year change of +4.6% [5]. - 'Revenues- Income from equity affiliates' is projected at $1.17 billion, reflecting a decline of 36.4% from the previous year [5]. - 'Revenues- Sales and other operating revenue- Specialty Products' is expected to be $7.16 billion, showing a significant increase of +55% year over year [6]. - 'Revenues- Sales and other operating revenue- Energy Products' is forecasted to reach $63.39 billion, indicating a slight decline of -1.3% from the prior year [6]. - 'Revenues- Sales and other operating revenue- Upstream- Non-U.S.' is estimated at $3.24 billion, down by 8% year over year, while 'Upstream- United States' is expected to rise by 161% to $5.72 billion [7]. - 'Revenues- Sales and other operating revenue- Chemical Products- Non-U.S.' is projected at $3.67 billion, a change of +0.6%, and 'Specialty Products- Non-U.S.' is expected to reach $5.31 billion, reflecting a +68.5% increase [8]. Production Estimates - Analysts project 'Oil-equivalent production per day' to be 4,584.05 KBOE/D, up from 3,784 KBOE/D in the same quarter last year [9]. - 'Natural gas production available for sale per day - Worldwide' is expected to reach 8,462.62 Mcf/D, compared to 7,362 Mcf/D a year ago [9]. - 'Net production of crude oil, natural gas liquids, bitumen and synthetic oil per day - Worldwide' is estimated at 3,139.27 thousand barrels, up from 2,557 thousand barrels in the same quarter last year [10]. - For the United States, 'Net production of crude oil, natural gas liquids, bitumen and synthetic oil per day' is projected at 1,395.05 thousand barrels, compared to 816 thousand barrels a year ago [11]. Stock Performance - Over the past month, Exxon shares have declined by 9%, while the Zacks S&P 500 composite has seen a minor decrease of 0.2% [12].
What Analyst Projections for Key Metrics Reveal About Ford Motor (F) Q1 Earnings
ZACKS· 2025-04-30 14:20
Core Viewpoint - Ford Motor Company is expected to report break-even quarterly earnings per share, indicating a 100% decline year-over-year, with revenues projected at $35.48 billion, reflecting an 11.1% decrease from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 8.7% over the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts project 'Revenues- Company excluding Ford Credit' to be $34.72 billion, a decrease of 13% from the year-ago quarter [5]. - 'Revenues- Ford Credit' is expected to reach $3.05 billion, showing a 5.2% increase year-over-year [5]. - 'Revenues- External Revenues- Ford Blue' is estimated at $18.21 billion, reflecting a 16.5% decline from the previous year [5]. - 'Revenues- Ford Pro' is forecasted at $16.41 billion, indicating an 8.8% decrease year-over-year [6]. - 'Revenues- External Revenues- Ford Model e' is projected at $809.82 million, representing a significant increase of 604.2% from the year-ago quarter [6]. Wholesale Units - 'Wholesale Units - Ford Blue' is expected to be 560.82 thousand, down from 626 thousand in the same quarter last year [6]. - 'Wholesale Units - Ford Pro' is projected at 354.08 thousand, compared to 409 thousand reported in the previous year [7]. - 'Wholesale Units - Ford Model e' is anticipated to reach 29.38 thousand, up from 10 thousand in the year-ago quarter [7]. Adjusted EBIT - 'Adjusted EBIT- Ford Credit' is estimated at $338.24 million, slightly up from $326 million in the previous year [8]. - 'Adjusted EBIT- Ford Blue' is projected at $239.79 million, a significant decrease from $905 million reported in the same quarter last year [8]. - 'Adjusted EBIT- Ford Pro' is expected to be $1.64 billion, down from $3.01 billion in the same quarter of the previous year [9]. Stock Performance - Over the past month, Ford Motor shares have recorded a return of +2.1%, while the Zacks S&P 500 composite has seen a -0.2% change [9].
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
ZACKS· 2025-04-30 12:55
Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].